[HTML][HTML] Study of the neurodegenerative process in Mucopolysaccharidosis type VII and its correction by gene therapy
A Onieva Salgado - 2023 - ddd.uab.cat
La mucopolisacaridosis tipus VII és un trastorn autosòmic recessiu causat per una
deficiència de β-glucuronidasa,(GUSB) que condueix a l'acumulació de glicosaminoglicans …
deficiència de β-glucuronidasa,(GUSB) que condueix a l'acumulació de glicosaminoglicans …
Mucopolysaccharidosis type I: current knowledge on its pathophysiological mechanisms
D Campos, M Monaga - Metabolic brain disease, 2012 - Springer
Mucopolysaccharidosis type I is one of the most frequent lysosomal storage diseases. It has
a high morbidity and mortality, causing in many cases severe neurological and somatic …
a high morbidity and mortality, causing in many cases severe neurological and somatic …
[PDF][PDF] Mucopolysaccharidosis type VI: natural history, diagnostic and therapeutic importance
JO Pereira, M Garbelini, VC Palazzo - Rev Neurocienc, 2011 - scholar.archive.org
Introduction. The mucopolysaccharidosis VI is caused by the deficiency of n-
acetilgalactosamina-4-sulfatase, one of eleven lysosomal enzymes responsible for …
acetilgalactosamina-4-sulfatase, one of eleven lysosomal enzymes responsible for …
Recent trends in mucopolysaccharidosis research
H Kobayashi - Journal of human genetics, 2019 - nature.com
Mucopolysaccharidosis (MPS) is a group of inherited conditions involving metabolic
dysfunction. Lysosomal enzyme deficiency leads to the accumulation of glycosaminoglycan …
dysfunction. Lysosomal enzyme deficiency leads to the accumulation of glycosaminoglycan …
[HTML][HTML] Treatment of brain disease in the mucopolysaccharidoses
M Scarpa, PJ Orchard, A Schulz, PI Dickson… - Molecular genetics and …, 2017 - Elsevier
The mucopolysaccharidosis (MPS) disorders are a group of lysosomal storage diseases
caused by lysosomal enzyme deficits that lead to glycosaminoglycan accumulation, affecting …
caused by lysosomal enzyme deficits that lead to glycosaminoglycan accumulation, affecting …
Gene transfer in murine MPS IIIA using canine adenoviral vectors.
AA Lau - 2007 - digital.library.adelaide.edu.au
Mucopolysaccharidosis type IIIA (MPS IIIA) is an autosomal-recessively inherited disorder
caused by the deficiency of lysosomal sulphamidase (NS) enzyme activity, resulting in the …
caused by the deficiency of lysosomal sulphamidase (NS) enzyme activity, resulting in the …
Progressive neurologic and somatic disease in a novel mouse model of human mucopolysaccharidosis type IIIC
S Marcó, A Pujol, C Roca, S Motas… - Disease models & …, 2016 - journals.biologists.com
Mucopolysaccharidosis type IIIC (MPSIIIC) is a severe lysosomal storage disease caused by
deficiency in activity of the transmembrane enzyme heparan-α-glucosaminide N …
deficiency in activity of the transmembrane enzyme heparan-α-glucosaminide N …
A prospective one-year natural history study of mucopolysaccharidosis types IIIA and IIIB: Implications for clinical trial design
KV Truxal, H Fu, DM McCarty, KA McNally… - Molecular genetics and …, 2016 - Elsevier
Mucopolysaccharidosis type III is a group of four autosomal recessive enzyme deficiencies
leading to tissue accumulation of heparan sulfate. Central nervous system disease is …
leading to tissue accumulation of heparan sulfate. Central nervous system disease is …
[HTML][HTML] Hematopoietic stem cell transplantation in mucopolysaccharidosis type IIIA: A case description and comparison with a genotype-matched control group
AF Köhn, L Grigull, M du Moulin, S Kabisch… - Molecular Genetics and …, 2020 - Elsevier
Abstract Background Mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo A syndrome) is a
chronic progressive neurodegenerative storage disorder caused by a deficiency of …
chronic progressive neurodegenerative storage disorder caused by a deficiency of …
Recommendations on clinical trial design for treatment of Mucopolysaccharidosis Type III
A Ghosh, E Shapiro, S Rust, K Delaney… - Orphanet journal of rare …, 2017 - Springer
Background Mucopolysaccharidosis type III is a progressive, neurodegenerative lysosomal
storage disorder for which there is currently no effective therapy. Though numerous potential …
storage disorder for which there is currently no effective therapy. Though numerous potential …